Tata Tech benches close to 400 employees amid COVID-19: Report

The employees will continue to be on the payroll and covered under the company health policy till 2020-end

Moneycontrol News

July 25, 2020 / 09:10 IST

Tata Technologies has reportedly put close to 400 employees on the bench - with many opting for paid leave, amid the ongoing coronavirus pandemic.

“In response to the changed business environment … we have undertaken several actions including optimisation of our bench resources,” said a Tata Technologies spokesperson said as per a report by The Economic Times.

They added that the move is among several actions taken to make the company “nimble, responsive and flexible.”

The employees will continue to be on the payroll and covered under the company health policy till 2020-end, they added. For benched employees that do not choose to go on leave, the other option is a statutory redundancy process.

Follow our LIVE Updates on the coronavirus pandemic here

COVID-19 Vaccine

Frequently Asked Questions

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

Show